Advanced search
Publication Cover
International Medical Case Reports Journal Volume 17, 2024 - Issue
Submit an article Journal homepage
124
Views
0
CrossRef citations to date
0
Altmetric
Case reports

HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

Jun ChengDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaView further author information
,
Jinjin PanDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaView further author information
,
Dongmei ZhaoDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaView further author information
,
Xuejiao MaDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaView further author information
,
Qiulin SunDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaView further author information
&
Jiabin LiDepartment of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 121-124 | Received 27 Oct 2023, Accepted 01 Feb 2024, Published online: 12 Feb 2024

References

  • Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
  • Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
  • Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20(22):6716–6724. doi:10.3748/wjg.v20.i22.6716
  • Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67(1):36–47. doi:10.1002/hep.29344
  • Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014;33(2):273–276. doi:10.1007/s10067-013-2378-0
  • Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9(3):156–166. doi:10.1038/nrclinonc.2012.1
  • Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximab-based treatment HCV replication, and hepatic flares. Clinical Dev Immunol. 2012;2012:945–950. doi:10.1155/2012/945950
  • Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138(5):1875–1884. doi:10.1053/j.gastro.2010.02.004
  • Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol. 2004;16:204–205.
  • Miura Y, Theriault RL, Naito Y, et al. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. J Cancer. 2013;4(6):519–523. doi:10.7150/jca.6231
  • Shoji H, Hashimoto K, Kodaira M, et al. Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection. Oncology. 2012;82(4):228–233. doi:10.1159/000336904
  • Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47(1):155–157. doi:10.1080/14639230500236818
  • Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J. 2008;49:86–89.
  • Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90(3):383–387. doi:10.1007/s12185-009-0386-2
  • Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc. 2010;42(3):843–845. doi:10.1016/j.transproceed.2010.02.038
  • Wang YD, Cui GH, You Y, Li M, Xia J, Hu Y. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi. 2012;33(9):743–746. doi:10.3760/cma.j.issn.0253-2727.2012.09.012
  • Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. Word J Gastroenterol. 2013;19(8):1318–1321. doi:10.3748/wjg.v19.i8.1318
  • Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2015;105(6):2473–2479. doi:10.1182/blood-2004-07-2527
  • Olivieri J, Coluzzi S, Attolico I, Olivieri A. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. Sci World J. 2011;11:1908–1931. doi:10.1100/2011/924954

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.